Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Healthtrust
Teva
Harvard Business School
Covington
Express Scripts
Citi
Moodys
Accenture

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,778,924

« Back to Dashboard

Which drugs does patent 8,778,924 protect, and when does it expire?

Patent 8,778,924 protects MOXATAG and is included in one NDA.

This patent has eleven patent family members in six countries.
Summary for Patent: 8,778,924
Title:Modified release amoxicillin products
Abstract: An amoxicillin product comprising: at least one modified release component(s), wherein the at least one modified release component(s) comprises at least amoxicillin and a pharmaceutically acceptable carrier; and wherein when administered to a patient or subject in the fed state said amoxicillin product exhibits a pharmacokinetic profile for amoxicillin in the plasma characterized as follows: (1) the ratio of the portion of the AUC as measured from 2 hours post-administration to 5 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 2.0:1; and (2) the ratio of the portion of the AUC as measured from 5 hours post-administration to 12 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 1.1:1.
Inventor(s): Flanner; Henry H. (Montgomery Village, MD), Tolle-Sander; Sanna (North Potomac, MD), Treacy; Donald (Woodbine, MD), Burnside; Beth A. (Bethesda, MD), Clausen; Susan P. (Ijamsville, MD)
Assignee: Shionogi Inc. (Florham Park, NJ)
Application Number:11/633,315
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 8,778,924

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vernalis R And D Ltd MOXATAG amoxicillin TABLET, EXTENDED RELEASE;ORAL 050813-001 Jan 23, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,778,924

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,299,052 Pharmaceutical compositions and methods for improved bacterial eradication ➤ Sign Up
8,357,394 Compositions and methods for improved efficacy of penicillin-type antibiotics ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Daiichi Sankyo
Queensland Health
Express Scripts
Chubb
Cantor Fitzgerald
Cipla
US Army
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.